IXP Launches Maiden Rs 2 Bn Fund to Fuel Biotech Innovation

14 Feb 2025 CW Team

The IXP Lifesciences Catalyst Fund is targeting a corpus of Rs 2 billion with a greenshoe option of Rs 1 billion. The fund plans to create a portfolio of 20-25 companies addressing gaps in the market for both services and products. Within the Lifesciences sector, the fund will invest across innovation in areas such as pharma, biotechnology, medical technology, speciality chemicals, agrotechnology and nutraceuticals.

Ketki Tulpule, Ph.D., CIO at IXP said, “IXP was born out of a need we saw in the Indian start-up ecosystem. In fact, we conducted a pan-India survey to understand the pain points of biotech’s for an outside-in perspective. The sector is nuanced, and requires investors with scientific expertise, industry knowledge, and operational experience to help biotech’s succeed. We are glad to have onboarded industry veterans as council members and advisors who add to the scientific heft of the fund”.

Vishal Goel, Partner at IXP and Co-founder of JV Ventures commented, “The Indian Lifesciences industry is dynamic with large untapped potential. Through IXP Venture Studio, we will co-create companies along with scientists for ideas addressing unmet needs in the market. Unlike traditional VCs, IXP has a hands-on approach through active participation from concept to scale. The Ventureprenuer Program has been designed to transform scientists into founders”.

Jasmeet Chhabra, Partner at IXP and Co-founder of JV Ventures added, “The success of biotech’s hinges on many factors, not just capital. These early-stage companies require access to larger ecosystems for laboratories, networks and R&D services which we provide through PoweRx, the Lifesciences vertical of JV Ventures. This differentiates IXP from other funds as it leverages synergies within the group to create a winning proposition for portfolio companies.”

Image Source:https://www.msn.com/

IXP, a Lifesciences VC backed by JV Ventures, has announced the launch of it’s first fund to invest in early-stage companies. The fund aims to build a portfolio of B2B companies ranging from Pre-seed to Series A stages. The IXP Lifesciences Catalyst Fund is targeting a corpus of Rs 2 billion with a greenshoe option of Rs 1 billion. The fund plans to create a portfolio of 20-25 companies addressing gaps in the market for both services and products. Within the Lifesciences sector, the fund will invest across innovation in areas such as pharma, biotechnology, medical technology, speciality chemicals, agrotechnology and nutraceuticals. Ketki Tulpule, Ph.D., CIO at IXP said, “IXP was born out of a need we saw in the Indian start-up ecosystem. In fact, we conducted a pan-India survey to understand the pain points of biotech’s for an outside-in perspective. The sector is nuanced, and requires investors with scientific expertise, industry knowledge, and operational experience to help biotech’s succeed. We are glad to have onboarded industry veterans as council members and advisors who add to the scientific heft of the fund”. Vishal Goel, Partner at IXP and Co-founder of JV Ventures commented, “The Indian Lifesciences industry is dynamic with large untapped potential. Through IXP Venture Studio, we will co-create companies along with scientists for ideas addressing unmet needs in the market. Unlike traditional VCs, IXP has a hands-on approach through active participation from concept to scale. The Ventureprenuer Program has been designed to transform scientists into founders”. Jasmeet Chhabra, Partner at IXP and Co-founder of JV Ventures added, “The success of biotech’s hinges on many factors, not just capital. These early-stage companies require access to larger ecosystems for laboratories, networks and R&D services which we provide through PoweRx, the Lifesciences vertical of JV Ventures. This differentiates IXP from other funds as it leverages synergies within the group to create a winning proposition for portfolio companies.” Image Source:https://www.msn.com/

Real Estate

14 May 2026

AIDO Launches Smart Hotel Lock for Hospitality Spaces

AIDO, an endorsed brand of dormakaba, has launched the AIDO Hotel Lock, designed to improve secure and seamless access management across hotels, serviced residences and institutional spaces. The solution combines smart security, operational efficiency and contemporary design to support modern hospitality requirements.The lock features integrated electronic mortise functionality, reverse lifting handle locking and compatibility with third-party property management system platforms, enabling smoother room access and check-in operations. Powered by 6V DC with four AA alkaline batteries, it offers..

Real Estate

14 May 2026

Häfele Unveils Zenith Digital Lock

Häfele has introduced the Zenith Digital Lock, designed to enhance home security through smart technologies and versatile locking functions. Finished in Black and Grey, the lock blends with modern interiors while offering a refined, tech-enabled access experience.The lock features Smart Password technology for secure access and added protection against password tracing. Its Smart Voice function provides guided assistance for easy operation, while Smart Freeze temporarily disables access after multiple incorrect attempts, strengthening safety and control.The Zenith Digital Lock also offers mul..

Infrastructure Urban

14 May 2026

KBL Revenue Rises 11 Per Cent in Q4 FY26

Kirloskar Brothers Limited reported consolidated revenue from operations of Rs 14.15 billion for Q4 FY26, compared to Rs 12.81 billion in Q4 FY25, registering around 11 per cent year-on-year growth. Consolidated Profit Before Tax stood at Rs 1.47 billion, against Rs 1.27 billion in the corresponding quarter last year. Profit After Tax stood at Rs 1.04 billion, compared to Rs 1.12 billion in Q4 FY25.For FY26, consolidated revenue from operations stood at Rs 45.38 billion, compared to Rs 44.92 billion in FY25. Consolidated Profit After Tax for the year was Rs 3.61 billion, against Rs 4.03 billio..